No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | Anastrozole | 2件: Anastrozole; Arimidex (anastrozole); | D00960 |
1件: CYP19A1 |
3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis |
3件: 78, 86, 193 |
2 | Beloranib | 2件: Beloranib; Subcutaneous beloranib in suspension; | - |
- |
- |
1件: 193 |
3 | Cannabidiol | 6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
14件: 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
4 | Cannabidivarin | - | - |
- |
- |
1件: 193 |
5 | Carbetocin | 3件: Carbetocin; Intranasal carbetocin dose 1; Intranasal carbetocin dose 2; | D07229 |
1件: OXTR |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
1件: 193 |
6 | Chloride ion | - | - |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
7 | Choline | 6件: Bis-choline tetrathiomolybdate; Choline; Choline chloride; Choline supplementation; Diazoxide choline controlled-release tablet; Vitamin: choline bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1; | D07690 |
- |
- |
4件: 65, 171, 193, 299 |
8 | Corticotropin | 8件: Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
12件: 2, 13, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 |
9 | Diazoxide | 2件: Diazoxide; Diazoxide choline controlled-release tablet; | D00294 |
2件: ABCC8, KCNJ11 |
4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
1件: 193 |
10 | Exenatide | 3件: Exenatide; Exenatide 10 micrograms; Exenatide 5 micrograms; | D04121 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 193, 233 |
11 | Guanfacine | 2件: Guanfacine; Guanfacine extended release (gxr); | D00606 D08031 |
1件: ADRA2A |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
1件: 193 |
12 | Liraglutide | 1件: Liraglutide; | D06404 |
1件: GLP1R |
3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
3件: 6, 75, 193 |
13 | Livoletide | 1件: Livoletide; | - |
- |
- |
1件: 193 |
14 | Medical air | 4件: Medical air; Medical air (sham o2); Medical air vs oxygen; Sham o2 (medical air); | - |
- |
- |
3件: 85, 86, 193 |
15 | Metoprolol | 6件: Metoprolol; Metoprolol succinate; Metoprolol succinate + doxazosin; Metoprolol tartrate 50 mg; Metoprolol tartrate oral tablet; Tesofensine/metoprolol; | D00601 D02358 D05011 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
7件: 17, 57, 58, 66, 113, 193, 226 |
16 | Metyrapone | 1件: Metyrapone; | D00410 D05019 |
1件: CYP11B1 |
4件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Steroid hormone biosynthesis |
2件: 75, 193 |
17 | Octreotide | 5件: Gallium-68-dota-n-octreotide; Octreotide; Octreotide lar; Octreotide lar / sandostatin lar (lar=long acting release); Octreotide-lar; | D00442 D06495 |
1件: SSTR2 |
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
8件: 67, 75, 84, 85, 89, 96, 193, 227 |
18 | Oxygen | 9件: Continuous oxygen; Helium / oxygen mixed gas inhalation therapy; Medical air vs oxygen; Medical grade oxygen; Nitric oxide plus oxygen; Oxygen; Oxygen 40 %; Oxygen supplementation; Perfluorinated gas/oxygen mixture; | D00003 |
- |
- |
18件: 5, 6, 17, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 211, 226, 299, 330 |
19 | Oxytocin | 6件: Intranasal oxytocin; Intranasal oxytocin (in-oxt); Oxytocin; Oxytocin (oxt) continuous; Oxytocin 24iu; Oxytocin 48iu; | D00089 |
1件: OXTR |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
4件: 127, 193, 206, 226 |
20 | Rimonabant | 1件: Rimonabant; | D05731 |
1件: CNR1 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
1件: 193 |
21 | Sodium chloride | 14件: 0.9% sodium chloride; 0.9% sodium chloride (normal saline); 0.9% sodium chloride injection; 0.9% w/v sodium chloride solution; Isotonic sodium chloride solution; Physiological serum (sodium chloride); Sodium chloride; Sodium chloride (7%); Sodium chloride 0,9%; Sodium chloride 6%; Sodium chloride solution; Sodium chloride solution 0.9%; Sodium chloride solvent; Sodium pyruvate in 0.9% sodium chloride solution; | D02056 |
- |
- |
19件: 6, 11, 13, 14, 17, 34, 46, 51, 53, 67, 78, 86, 97, 168, 193, 227, 228, 288, 299 |
22 | Somatotropin | 2件: Recombinant human somatotropin; Somatotropin; | D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
18件: 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
23 | Tesofensine | 3件: 1. tesofensine (ns 2330); Tesofensine; Tesofensine/metoprolol; | - |
- |
- |
2件: 6, 193 |
24 | Topiramate | 2件: Topiramate; Topiramate (drug); | D00537 |
36件: CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
48件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Arrhythmogenic right ventricular cardiomyopathy (ARVC), Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 6, 140, 144, 156, 193 |
25 | Ubidecarenone | - | D01065 |
- |
- |
12件: 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |
26 | Water | 13件: 15 o water; 15-o labeled water; 5% glucose water solution; Dextrose, 5% in water; High water intake; Lactose in water; Pl 12185/0002 & pl 12185/0005(water for injection); Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; Water; Water for injection; Water for injections; Water for injections, ep; | D00001 |
- |
- |
22件: 2, 5, 6, 13, 17, 19, 28, 35, 46, 53, 57, 63, 65, 67, 78, 84, 97, 193, 226, 271, 278, 299 |